68 Harley Street London, W1G 7HE · Main Office
Also at Cromwell & Syon Bishops Wood · Multiple Locations
0203 9838 001 Call for Appointments
jessica@oneheartclinic.com Rapid Response to Enquiries
Cardiac Condition
Understanding Cardiomyopathy
A family of conditions in which the heart muscle itself is diseased — not the arteries, not the valves, but the muscle. Each type has a distinct cause, a specific pattern on investigation, and increasingly targeted treatment.
Overview
What Is Cardiomyopathy?
Cardiomyopathy is a disease of the heart muscle — the myocardium — in which the muscle fibres themselves are structurally or functionally abnormal, independent of any problem with the coronary arteries or heart valves.
The word itself means "disease of the heart muscle" (cardio = heart; myo = muscle; pathy = disease). Unlike coronary artery disease, where the problem is a blocked blood vessel supplying the heart, cardiomyopathy is a primary disease of the muscle tissue itself. The arteries can be completely normal — yet the heart muscle is thickened, dilated, stiff, or infiltrated with abnormal protein.
Cardiomyopathy is not a single condition. It is a family of distinct diseases, each with different genetic underpinnings, different clinical patterns, and — increasingly — different targeted treatments. Accurate classification is therefore not merely an academic exercise: it directs treatment, determines prognosis, and identifies which family members need to be screened.
Many patients are referred after a routine echocardiogram or ECG raises an unexpected finding. Others come with breathlessness, palpitations, or a family history of sudden death. In all cases, the investigation approach is the same: to characterise the condition precisely before making any treatment decision.
1 in 500 Adults carry the gene for hypertrophic cardiomyopathy — the most common inherited heart disease
No. 1 Cause of sudden cardiac death in young athletes — predominantly from undiagnosed HCM
50% Chance a first-degree relative carries the same pathogenic gene variant as an affected family member
30% Reduction in mortality demonstrated with tafamidis in ATTR cardiac amyloidosis — now treatable
Classification
The Five Types of Cardiomyopathy
Each type of cardiomyopathy has a distinct mechanism, a characteristic imaging appearance, and a specific treatment pathway. The distinction matters — a treatment that helps one type may be harmful in another.
HCM
Hypertrophic Cardiomyopathy
The heart wall that thickens beyond all reason
The most common inherited heart muscle disease. One or more walls of the left ventricle become abnormally thick — not from high blood pressure or a valve problem, but because of a genetic mutation in the proteins that form the heart's contractile machinery. The most commonly affected genes are MYBPC3 and MYH7. The thickened wall can obstruct blood flowing out of the heart and — in a minority — creates a substrate for dangerous ventricular arrhythmia. In many patients, symptoms are mild and well-controlled; in others, the condition requires significant intervention.
Key: outflow tract obstruction in 70%; leading cause of sudden death in athletes under 35
DCM
Dilated Cardiomyopathy
The heart that stretches and weakens
The left ventricle — and often the right — becomes dilated and weakened, reducing the ejection fraction and impairing the heart's ability to pump. DCM is the most common cause of heart failure in patients under 60 and a frequent indication for cardiac transplant assessment. Around 25–30% of cases are familial, most commonly caused by mutations in the TTN gene (which encodes titin, the largest protein in the body) or LMNA (which carries a particularly high risk of arrhythmia and sudden death). Other causes include viral myocarditis, alcohol excess, and chemotherapy toxicity — some of which may partially or fully recover with treatment.
Key: LMNA mutation confers high arrhythmia risk — early ICD decision critical
ARVC
Arrhythmogenic Right Ventricular Cardiomyopathy
The heart that replaces muscle with fat and scar
A genetic disease of the desmosomes — the proteins that anchor heart muscle cells together. When these fail, the cells progressively die and are replaced by fatty and fibrous tissue, predominantly in the right ventricle. This creates an electrically unstable substrate prone to ventricular tachycardia and ventricular fibrillation, particularly during intense exercise. ARVC accounts for around 10–15% of sudden cardiac deaths in young athletes. The most commonly affected gene is PKP2 (plakophilin-2). A cardinal feature of ARVC management is exercise restriction — vigorous sport is known to accelerate disease progression and increase arrhythmia risk.
Key: exercise restriction is mandatory — even mild-to-moderate sport accelerates progression
Amyloid CM
Cardiac Amyloidosis
The heart silently infiltrated by rogue protein
Abnormal amyloid protein is deposited progressively within the heart muscle walls, causing them to stiffen and thicken. There are two principal types: transthyretin (ATTR) amyloidosis — in which the liver-produced TTR protein misfolds — and AL (light chain) amyloidosis — driven by a plasma cell dyscrasia in the bone marrow. Wild-type ATTR (previously called senile amyloidosis) is now recognised as surprisingly common in older men with heart failure and a preserved ejection fraction, and was almost universally underdiagnosed for decades. The outlook has been transformed by specific disease-modifying therapies. Early identification is everything — before the amyloid burden becomes overwhelming.
Key: now treatable with tafamidis — underdiagnosis remains the greatest barrier to care
Takotsubo
Takotsubo Cardiomyopathy
The heart broken by shock — and then rebuilt
Named after the Japanese octopus pot whose shape mirrors the ballooned left ventricle, Takotsubo is a transient cardiomyopathy triggered by intense physical or emotional stress — bereavement, fright, a medical procedure, or an unexpected shock. The surge of catecholamines (adrenaline) stuns the apex of the left ventricle, causing it to balloon outward while the base contracts normally. The condition mimics a heart attack — with chest pain, ECG changes, and elevated troponin — but the coronary arteries are unobstructed. Most patients make a full recovery within weeks, though the condition can rarely be life-threatening acutely. It predominantly affects post-menopausal women.
Key: usually fully reversible — coronary angiogram confirms clean arteries and clinches the diagnosis
Presentation
Symptoms & Warning Signs
Cardiomyopathy can be silent for years or even decades — discovered only because a relative was diagnosed, or because a routine ECG triggered a referral. When symptoms do occur, they arise from one of three mechanisms: impaired pump function, electrical instability, or outflow tract obstruction.
Breathlessness On exertion initially, then at rest in advanced disease. Caused by elevated filling pressures or reduced pump function.
Palpitations Irregular beats, runs of fast rhythm, or sustained ventricular tachycardia. Particularly prominent in ARVC and DCM with LMNA mutations.
Exertional chest pain In HCM, obstruction of the outflow tract reduces coronary perfusion pressure during exercise — causing ischaemic-type pain without blocked arteries.
Pre-syncope & blackouts Transient loss of consciousness during or just after exercise is a high-risk symptom requiring urgent assessment.
Ankle swelling Peripheral oedema from fluid retention — more common in DCM and amyloidosis than in HCM.
Fatigue & reduced tolerance A gradual decline in what a patient can do — often attributed to ageing, deconditioning, or anaemia before a cardiac cause is sought.
Red Flag — Seek Urgent Assessment Blackout during exercise • Resuscitated cardiac arrest • Family history of sudden death under age 50 • Sustained ventricular tachycardia on a Holter monitor • Unexplained syncope in a known cardiomyopathy patient. These symptoms require assessment within days, not weeks.
Many patients with cardiomyopathy are entirely asymptomatic — discovered only on screening. The absence of symptoms does not mean the absence of risk. Structural and electrical abnormalities can be present and progressive in patients who feel completely well.
Cardiomyopathy & Sport
Sport and vigorous exercise are beneficial for most cardiac conditions — but cardiomyopathy is different. In HCM, competitive sport is generally restricted because high-intensity exercise is associated with an increased risk of sudden death in those with adverse features. In ARVC, even moderate-intensity endurance exercise is known to accelerate disease progression and promote arrhythmia — making sport restriction one of the most important interventions available.
Exercise guidance is individualised. Dr Nijjer undertakes formal risk stratification — including exercise stress testing and ambulatory monitoring — before advising on what each patient can safely do. Many patients with cardiomyopathy can continue low-to-moderate physical activity; the aim is to protect, not to over-restrict.
Experienced in Complex Cardiomyopathy Dr Nijjer has extensive experience assessing patients with all forms of cardiomyopathy across both NHS and private practice, including patients referred from other hospitals where the diagnosis remained unclear.
Investigation
How Cardiomyopathy Is Diagnosed
Cardiomyopathy diagnosis is a process of layered investigation — each test adds a further dimension to the picture, refining both the type and the severity, until a complete characterisation is possible.
- ECG Often the first abnormal finding — and frequently the trigger for referral. HCM typically shows left ventricular hypertrophy, deep Q waves in lateral leads, and T-wave changes. ARVC shows epsilon waves and T-wave inversions in the right precordial leads. Amyloidosis produces a classic voltage-thickness mismatch — a pseudo-infarct pattern with low voltages despite a thick wall on echo.
- Echocardiogram First-line structural imaging. Measures wall thickness, chamber dimensions, ejection fraction, filling pressures, and valve function. In HCM, identifies the pattern and degree of hypertrophy and whether the outflow tract is obstructed. In amyloidosis, shows a characteristic granular sparkling texture and abnormal diastolic function.
- Cardiac MRI The most powerful diagnostic tool. MRI characterises the myocardium in ways no other test can: it measures wall motion, quantifies fibrosis via late gadolinium enhancement (LGE), and distinguishes fat from scar. Each cardiomyopathy type has a characteristic LGE pattern — mid-wall enhancement in DCM, basal septal enhancement in HCM, fatty infiltration and ring-like enhancement in ARVC, diffuse subendocardial enhancement in amyloid. This pattern frequently clinches the diagnosis.
- Holter / Ambulatory ECG 24- to 14-day ambulatory ECG monitoring identifies arrhythmias — non-sustained ventricular tachycardia (NSVT) in HCM and ARVC, and atrial fibrillation in all types. NSVT is a key input into the HCM SCD risk score.
- Exercise Stress Test Provides information on exercise capacity, blood pressure response (blunted or hypotensive response in HCM is an adverse sign), ECG changes under load, and provocation of outflow gradient. Also helps with individual exercise advice and fitness assessment.
- Technetium bone scan (DPD) A nuclear medicine scan using a bone tracer that — counterintuitively — binds avidly to amyloid deposits in the heart. In the context of a negative serum free light chain test, a grade 2–3 uptake on DPD scanning is virtually diagnostic of ATTR cardiac amyloidosis without the need for a biopsy. This non-invasive pathway has revolutionised amyloid diagnosis.
- Blood tests NT-proBNP (heart stress marker, elevated in all types), troponin, renal function, thyroid function. For amyloidosis: serum free light chains and serum protein electrophoresis (SPEP) to exclude AL amyloid. For haemochromatosis: transferrin saturation and ferritin.
- Genetic testing A multi-gene cardiomyopathy panel identifies the causative variant in around 40–60% of patients with familial HCM and a similar proportion in DCM and ARVC. A positive result enables predictive cascade testing of relatives — transforming an individual diagnosis into a family-wide opportunity to intervene early.
Cardiac MRI is the most powerful tool for characterising the type and extent of cardiomyopathy — with a specific pattern for each diagnosis
The voltage-thickness mismatch — low electrical voltage on ECG despite a thick wall on echo — is one of the most telling findings in cardiology, and should always prompt consideration of cardiac amyloidosis rather than hypertensive heart disease.
In HCM, the HCM Risk-SCD calculator uses age, wall thickness, left atrial size, outflow gradient, family history of sudden death, NSVT, and unexplained syncope to quantify the 5-year sudden death risk — guiding the decision on whether to recommend an implantable defibrillator.
Management
Treating Cardiomyopathy
Treatment varies fundamentally by type. What helps HCM can be harmful in ARVC. What is transformative in amyloidosis has no role in Takotsubo. The correct treatment requires the correct diagnosis — which is why accurate classification is the first priority of every consultation.
Treatment decisions in cardiomyopathy require precise diagnosis — each type demands a different strategy
- HCM — Symptom Relief & Outflow Obstruction Beta-blockers (metoprolol, bisoprolol) and verapamil reduce heart rate and wall stress, improving filling and relieving obstruction symptoms. Disopyramide, a powerful sodium-channel blocker, can further reduce outflow gradient. For eligible patients with severe obstruction refractory to maximal medical therapy: surgical myectomy (open-heart surgery to remove part of the thickened wall) or alcohol septal ablation (catheter-based procedure to selectively scar and reduce the obstructing muscle). Both achieve excellent long-term results in experienced hands.
- Mavacamten — A New Era for HCM New drug class Mavacamten (Camzyos) is the first selective cardiac myosin inhibitor — the first drug to treat the root cause of HCM rather than its consequences. By modulating the contractile machinery directly, it reduces the hypercontractility that drives outflow obstruction and symptoms. The EXPLORER-HCM trial demonstrated dramatic improvements in exercise capacity, outflow gradient, and symptoms compared to placebo. It is now licensed in the UK for patients with obstructive HCM and NYHA Class II–III symptoms, and represents a genuine step-change in care.
- DCM — Four Pillars of Heart Failure Therapy Patients with DCM and a reduced ejection fraction benefit from the same four-pillar guideline-directed therapy as other causes of heart failure: sacubitril-valsartan (ARNI), beta-blocker, MRA, and SGLT2 inhibitor. In LMNA-mutation DCM, an ICD is recommended early given the disproportionate arrhythmia risk — at a higher ejection fraction threshold than other DCM subtypes. CRT is offered where a broad left bundle branch block coexists.
- ARVC — Arrhythmia Suppression & Prevention Medical management includes antiarrhythmic drugs — most commonly sotalol or amiodarone — to suppress ventricular ectopy and reduce VT burden. An ICD is recommended for patients with sustained VT, resuscitated arrest, or high-risk features. Catheter ablation can reduce the frequency of ICD shocks in patients with recurrent VT. Critically, exercise restriction is itself a treatment — and may be the most important one.
- Takotsubo — Supportive Care & Recovery Most patients recover completely within four to twelve weeks. Management is supportive: heart failure therapies if needed acutely, monitoring for complications (arrhythmia, outflow obstruction, and rarely left ventricular thrombus), and psychological support given the emotional trigger. ACE inhibitors are typically continued for several months while the ventricle recovers. Recurrence is uncommon but can occur with a further stressor. A repeat echocardiogram at 3–6 months confirms full recovery.
- ICD — Sudden Cardiac Death Prevention An implantable cardioverter-defibrillator is a central part of management for patients across multiple cardiomyopathy types who carry an elevated risk of sudden cardiac death. The decision is guided by a combination of the underlying diagnosis, ejection fraction, arrhythmia history, genetic variant, and validated risk scores (particularly the HCM Risk-SCD model). Newer subcutaneous ICD (S-ICD) technology avoids leads inside the heart and is increasingly preferred in younger patients with cardiomyopathy.
Spotlight
Cardiac Amyloidosis
The Diagnosis That Changes Everything
For decades, cardiac amyloidosis was considered untreatable and was diagnosed only at autopsy. In the last ten years, a diagnostic revolution and a series of transformative drug trials have changed this condition from one of the most feared to one of the most exciting in cardiology.
The Hidden Clues — What Patients Already Knew
Cardiac amyloidosis rarely appears without warning. Looking back, most patients with ATTR amyloidosis have a history of one or more of the following — each a clue that amyloid protein was depositing in tissues years before the heart diagnosis was made.
Carpal Tunnel Syndrome
Bilateral carpal tunnel surgery — especially before age 60 — is present in over 40% of ATTR amyloidosis patients, often decades before cardiac involvement. The syndrome occurs because amyloid deposits compress the median nerve at the wrist.
Lumbar Spinal Stenosis
Amyloid deposits within the spinal canal cause narrowing and nerve compression, producing back pain and leg symptoms. Spinal stenosis surgery in an older man with heart failure should prompt amyloid screening.
Bicep Tendon Rupture
The distinctive "Popeye sign" — a bulging proximal bicep from spontaneous tendon rupture — is strongly associated with ATTR amyloidosis. Rupture without significant trauma in an older patient is a major clinical clue.
Peripheral Neuropathy
Numbness, tingling, or pain in the feet and legs from amyloid deposits around peripheral nerves — particularly prominent in hereditary ATTR variants. Often attributed to diabetes or age-related neuropathy and not investigated further.
Diagnosis
How Amyloidosis Is Detected
The investigation pathway for suspected cardiac amyloidosis is highly specific. The ECG hallmark is a pseudo-infarct pattern with low voltages — despite the echo showing a thick-walled heart. This voltage-thickness mismatch is one of the most important clinical signs in cardiology.
Cardiac MRI reveals a characteristic diffuse subendocardial late gadolinium enhancement pattern and an inability to null the myocardium — a distinctive feature that reflects protein infiltration throughout the muscle.
The most elegant diagnostic advance is the technetium bone scintigraphy (DPD or HMDP scan). A radiotracer originally developed to image bones is injected intravenously — and then, unexpectedly, lights up the heart in ATTR amyloidosis. A grade 2 or 3 cardiac uptake, combined with the absence of a monoclonal protein in the blood and urine, is virtually diagnostic of ATTR cardiac amyloidosis without the need for a biopsy.
Serum free light chains and protein electrophoresis are essential — they exclude AL amyloidosis, which requires a completely different treatment approach. AL amyloidosis is a haematological emergency: it progresses rapidly and requires urgent referral for plasma cell-directed therapy.
Treatment — A Revolution in Outcomes
Disease-Modifying Therapy
ATTR Amyloidosis
Tafamidis (Vyndaqel)
A TTR stabiliser that prevents the transthyretin protein from misfoldnig and assembling into amyloid fibrils. The landmark ATTR-ACT trial demonstrated a 30% reduction in all-cause mortality and a 32% reduction in cardiovascular hospitalisation over 30 months — results that transformed how this condition is managed. An oral daily tablet. Approved in the UK for ATTR cardiomyopathy.
Hereditary ATTR
Patisiran (Onpattro) and Vutrisiran (Amvuttra) are RNA interference therapies that silence the TTR gene in the liver, preventing production of the misfolded protein entirely. Eplontersen is an antisense oligonucleotide with a similar mechanism. These agents have shown remarkable results in hereditary ATTR with polyneuropathy and are increasingly studied in cardiac ATTR. Acoramidis (Attruby) is a newer, more potent stabiliser recently approved in the US and under review.
AL Amyloidosis
Directed at the underlying plasma cell clone in the bone marrow — not at the heart directly. Regimes include daratumumab-based chemotherapy (daratumumab + cyclophosphamide + bortezomib + dexamethasone: Dara-CyBorD), followed by autologous stem cell transplant in eligible patients. Haematology and cardiology teams manage these patients jointly. The cardiac outcome depends on how quickly the haematological response can be achieved.
Symptomatic Care
Diuretics manage fluid overload — but must be used cautiously as amyloid hearts are preload-dependent and can deteriorate rapidly if dehydrated. Standard heart failure drugs (ACE inhibitors, beta-blockers) are often poorly tolerated. Anticoagulation is important: AF is common in amyloidosis and embolic risk is high. An ICD is considered for high-risk patients.
Genetics
Protecting Your Family
A diagnosis of cardiomyopathy in one family member opens a window of opportunity for all the others. Because most cardiomyopathies are inherited in an autosomal dominant pattern, each first-degree relative has a 50% probability of carrying the same pathogenic variant. Many will be completely asymptomatic — yet the condition may be silently progressing, and early detection means early protection.
The process begins with index patient genetic testing — a comprehensive cardiomyopathy panel examining 50 or more genes in a single blood test. When a pathogenic or likely pathogenic variant is identified, the result becomes the key that unlocks the family. Each relative can then undergo targeted cascade testing — a single, inexpensive blood test looking only at the specific variant already found — rather than a full panel.
Relatives who test positive — even with no symptoms and a currently normal echocardiogram — are enrolled in regular clinical surveillance. This is not idle monitoring: it allows the earliest signs of structural change to be identified, ensures timely initiation of treatment before the heart deteriorates significantly, and — in conditions such as ARVC — allows lifestyle guidance (exercise restriction) to be given before any irreversible damage occurs.
Relatives who test negative — confirmed not to carry the family variant — are discharged from further cardiac monitoring with certainty. The anxiety of "not knowing" is resolved in a single appointment.
Genetic testing does not always provide a clear answer. Around 40–60% of cardiomyopathy cases have an identifiable variant. A "negative" genetic test does not exclude familial disease — relatives still require clinical screening even when no causative gene is found.
Who Should Be Screened?
Parents
The affected parent can usually be identified — and unaffected parents reassured. Older parents may have mild or subclinical disease not previously noticed.
Siblings
50% chance of carrying the same variant. Often the most practically important group — adults in their working years who may be exercising intensively without knowing they have a condition.
Children
Predictive genetic testing is generally offered from age 10–12 for HCM and ARVC. An earlier age may be appropriate if the condition is severe or sport participation is a concern.
Key Genes by Condition
| Condition | Common Genes | Clinical Note |
|---|---|---|
| HCM | MYBPC3, MYH7 | Together account for >70% of genotype-positive HCM |
| DCM | TTN, LMNA, SCN5A, RBM20 | LMNA: high arrhythmia risk; early ICD regardless of EF |
| ARVC | PKP2, DSP, DSG2, DSC2 | PKP2 most common; exercise worsens disease in all variants |
| ATTR Amyloid | TTR (Val30Met, Val122Ile) | Val122Ile more common in African ancestry; earlier cardiac onset |
Cascade genetic testing — one positive result, an entire family screened and protected
Further Information
Patient Resources
The Cardiomyopathy UK charity provides excellent patient guides for HCM, DCM, ARVC, and Takotsubo — including information on genetic testing, travel, insurance, sport, and employment. The British Heart Foundation also has resources covering living with inherited heart conditions.
For amyloidosis specifically, the UK Amyloidosis Support Group offers peer support, news on clinical trials, and guidance for patients and families navigating a new diagnosis.
Related Conditions
You May Also Find Helpful
A Cardiomyopathy Diagnosis
Deserves Expert Precision
Whether you have a new diagnosis, a family history of cardiomyopathy, or you feel your current treatment needs review, Dr Nijjer offers comprehensive specialist assessment — including advanced imaging, genetic counselling coordination, and access to the latest therapies.